Pfizer and risk

There’s an interesting article over at thestreet.com about how Pfizer (PFE) is more risky now than it has been in the past. This makes me stop and think because one of the things that attracted me to Pfizer was my perception that it was low-risk…

The risk doesn’t seem to be too great for the next year or two, but after that, it may be tough to meet growth expectations as Pfizer needs huge blockbuster drugs to help it grow now and current prices in the US may be unsustainable. The summer outlook may not be so great either, as campaign rhetoric sometimes likes to criticize the drug companies for making drugs so hard to get a hold of for poor (and in many cases the drugs are too expensive for not so poor) people.

Comments are closed.